BC Week In Review | Jan 18, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Extra | Jan 17, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Week In Review | Feb 16, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
BC Extra | Feb 9, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

Boehringer Ingelheim GmbH (Ingelheim, Germany) discontinued development of BI 409306 to treat Alzheimer's disease after the candidate missed the efficacy endpoints in two Phase II trials in the indication. BI 409306 is a phosphodiesterase-9A (PDE-9A)...
BC Innovations | Aug 4, 2016
Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...
Items per page:
1 - 5 of 5